For cervical cancer, therapies targeting MLL2 or m5C regulators like NSUN2 could restore immune recognition, while in ovarian cancer, inhibiting SETDB1 or KDM5A could enhance T-cell responses. Here, SETDB1 is linked to ovarian carcinoma.